Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A 24-week multicentre, observational study to evaluate the efficacy, tolerability and efficacy of the combination of vildagliptin plus metformin in Turkish patients with type 2 diabetes mellitus.

Next Previous
X
Search
Trial Profile

A 24-week multicentre, observational study to evaluate the efficacy, tolerability and efficacy of the combination of vildagliptin plus metformin in Turkish patients with type 2 diabetes mellitus.

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 03 Sep 2015

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Vildagliptin (Primary) ; Metformin
  • Indications Type 2 diabetes mellitus
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms GALATA

    • Most Recent Events

    • 06 Dec 2013 New trial record
    • 06 Nov 2013 Results presented at the 16th Annual European Conference of the International Society for Pharmacoeconomics and Outcomes Research.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top